Clinical Analysis of Small Cell Lung Cancer with Bone Marrow Metastases.
10.3779/j.issn.1009-3419.2018.05.08
- Author:
Yiqun CHE
1
;
Yang LUO
2
;
Di WANG
1
;
Di SHEN
1
;
Lin YANG
3
Author Information
1. Department of Clinical Laboratory, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Medical oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
3. Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Bone marrow metastases;
Lung neoplasmas;
Prognosis;
Small cell cancer
- MeSH:
Aged;
Bone Marrow;
pathology;
Bone Marrow Neoplasms;
mortality;
pathology;
secondary;
Female;
Humans;
Lung Neoplasms;
pathology;
Male;
Middle Aged;
Neoplasm Metastasis;
Retrospective Studies;
Small Cell Lung Carcinoma;
pathology
- From:
Chinese Journal of Lung Cancer
2018;21(5):403-407
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Small cell lung cancer (SCLC) is highly malignant and prone to bone marrow metastasis in early stage, but its related reports are limited. This study analyzed the clinical feature, laboratory examination, treatment and prognosis of SCLC patients with bone marrow metastasis.
METHODS:The clinical data of 26 SCLC patients with bone marrow metastasis were analyzed retrospectively. Prognostic factors were evaluated.
RESULTS:The median age of 26 patients was 57 years and the median time from diagnosis of SCLC to confirmed bone marrow metastases was 8 d. Most patients (96.2%) were accompanied by other organ metastases. The most common laboratory abnormalities were elevated lactate dehydrogenase in 19 cases (73.1%), thrombocytopenia and elevated alkaline phosphatase respectively in 11 cases (42.3%) and anemia in 7 cases (26.9%). Twenty patients had received chemotherapy and the remaining 6 patients had not. Of this group, 16 patients received at least 2 cycles of chemotherapy after the diagnosis of bone marrow metastasis. The median survival time was 15.7 wk (0.1 wk-82.9 wk) after diagnosis of bone marrow metastasis. The survival of patients with chemotherapy was significantly better than that of those without chemotherapy (χ²=33.768, P<0.001). Multivariate analysis showed that no chemotherapy was independent poor prognostic factors (P<0.05).
CONCLUSIONS:The SCLC patients with bone marrow metastasis have short survival, whereas chemotherapy can extend the survival of patients.
